Factors associated with unfavourable treatment outcomes in people with HIV-associated tuberculosis in Armenia, 2015 to 2019.


Journal

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
ISSN: 1122-0643
Titre abrégé: Monaldi Arch Chest Dis
Pays: Italy
ID NLM: 9307314

Informations de publication

Date de publication:
14 Jan 2021
Historique:
received: 20 10 2020
accepted: 11 11 2020
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 26 11 2021
Statut: epublish

Résumé

To evaluate factors associated with tuberculosis (TB) treatment outcomes in human Immunodeficiency Virus-Associated (HIV) TB patients in Armenia, we conducted a nation-wide cohort study using routine programmatic data of all HIV-associated TB patients receiving TB treatment with first- or second-line drugs from 2015 to 2019. Data were obtained from the TB and HIV electronic databases. We analysed occurrence of the combined unfavourable outcome (failure, lost to follow-up, death and not evaluated) and death separately, and factors associated with both outcomes using Cox regression. There were 320 HIV-associated TB patients who contributed a total of 351 episodes of TB treatment. An unfavourable TB treatment outcome was registered in 155 (44.2%) episodes, including 85 (24.2%) due to death, 38 (10.8%) lost to follow up, 13 (3.7%) failure and 19 (5.4%) not evaluated. Multivariable analysis showed that receipt of Antiretroviral Treatment (ART) [ART start before TB treatment: adjusted hazard ratio (aHR)=0.3, 95% confidence interval (CI): 0.2-0.5, aHR=, 95% CI:, 95% CI:, 95% CI:TB meningitis (aHR=4.4, 95% CI: 1.6-11.9) increased the risk. The risk of death was affected by the same factors as above in addition to the low BMI (aHR=2.5, 95% CI: 1.3-4.5) and drug resistance (aHR=2.3, 95% CI: 1.0-5.4). In the subsample of episodes receiving ART, history of interruption of ART during TB treatment increased the risk of unfavourable outcome (aHR=2.1 95% CI: 1.2-3.9), while ART start during TB treatment was associated with lower risk of both unfavourable outcome (within first 8 weeks: aHR: 0.5, 95% CI: 0.3-0.9; after 8 weeks: aHR: 0.4, 95% CI: 0.2-1.0) and death (within first 8 weeks: aHR: 0.2, 95% CI: 0.1-0.4; after 8 weeks: aHR: 0.1, 95% CI: 0.01-0.3). The rates of unfavourable TB treatment outcomes, and death in particular, among HIV-associated TB patients in Armenia are high. Our findings emphasize the protective effect of ART and the importance of proper management of cases complicated by drug resistance or meningitis.

Identifiants

pubmed: 33470082
doi: 10.4081/monaldi.2021.1648
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Auteurs

Lilit Gevorgyan (L)

Yerevan State Medical University after Mkhitar Heratsi, Yerevan. tiliagevorgyan@yahoo.com.

Ruzanna Grigoryan (R)

Tuberculosis Research and Prevention Center, Yerevan. ruzanna.grigory@gmail.com.

Kostyantyn Dumchev (K)

Ukrainian Institute on Public Health Policy, Kyiv. dumchev@uiphp.org.ua.

Kristina Akopyan (K)

Tuberculosis Research and Prevention Center, Yerevan. dr.akopian@gmail.com.

Anush Khachatryan (A)

National Center of Pulmonology, State Non Commercial Organization of the Ministry of Health, Abovyan. arm_anush@mail.ru.

Eduard Kabasakalyan (E)

National Tuberculosis Reference Laboratory of the National Center of Pulmonology, National Center of Pulmonology, State Non Commercial Organization of the Ministry of Health, Abovyan. eduard.kabasakalyan@gmail.com.

Trdat Grigoryan (T)

National Center for AIDS Prevention, National Center of Pulmonology, State Non Commercial Organization of the Ministry of Health, Yerevan. gtrdat@yahoo.com.

Marina Safaryan (M)

Yerevan State Medical University after Mkhitar Heratsi, Yerevan. marina-safaryan@rambler.ru.

Vardan Avagyan (V)

National Center of Pulmonology, State Non Commercial Organization of the Ministry of Health, Abovyan. vardan.avagyan@inbox.ru.

Sayohat Hasanova (S)

World Health Organization, Regional Office for Europe, Copenhagen. hasanovas@who.int.

Alberto Matteelli (A)

University of Brescia, WHO collaborating center for TB/HIV and TB elimination, Brescia. alberto.matteelli@unibs.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH